Ashland’s Strong Q3 Sales Growth Masks Deeper Operational Hurdles

WILMINGTON, Del. – July 28, 2026 – At first glance, Ashland Inc.’s third-quarter results paint a picture of robust health. The specialty ingredients company posted a 7% year-over-year sales increase to $497 million, beating analyst expectations and prompting a stock surge to a 52-week high. Driven by what CEO Guillermo Novo called “broad-based demand and strong commercial execution,” the company confidently reaffirmed its full-year guidance. Yet, beneath this bullish top line lies a more complex story of operational friction and diverging segment fortunes that savvy investors are watching closely.

While sales volumes climbed an impressive 6% across the board, Adjusted EBITDA fell 4% to $109 million. This divergence between revenue and earnings isn't just a statistical blip; it's a clear signal of the challenges simmering within Ashland's manufacturing network. The company is navigating a complex environment where booming demand in some sectors is being partially offset by the costly hangover from past production problems. This quarter reveals a company firing on some cylinders, but still working to get the entire engine running smoothly.

A Tale of Two Segments

The story of Ashland's third quarter is best told through its segmented performance, which reveals a stark contrast between its consumer-facing divisions and its more industrial-focused units. The Life Sciences and Personal Care segments were the undisputed stars of the show, demonstrating the resilience of their end-markets and the success of Ashland’s strategic focus.

Life Sciences sales surged 11% to $180 million, with its pharma business marking a fifth consecutive quarter of year-over-year volume growth. The company cited broad demand across all regions and product categories, particularly in high-purity excipients and injectables. “Life Sciences delivered double-digit sales gains, benefiting from broad demand across pharma and continued progress from our globalize and innovate strategies,” Novo stated in the release. The segment’s Adjusted EBITDA climbed in lockstep, up 11% to $60 million, underscoring its role as a powerful profit engine for the company.

Similarly, Personal Care sales grew a healthy 5% to $155 million, propelled by strong demand for biofunctional actives and high-single-digit growth in skin care. The performance highlights a successful push into higher-value, innovative products that resonate with current consumer trends toward sustainable and effective ingredients. The segment’s Adjusted EBITDA rose to $45 million from $41 million a year ago, proving its own ability to translate top-line growth into bottom-line results.

However, this strength was counteracted by weakness elsewhere. The Specialty Additives and Intermediates segments, while posting modest sales gains, saw their earnings decline, dragging down the company’s consolidated profitability. This disparity reveals the core challenge for Ashland: leveraging the momentum in its high-performing units while fixing the operational drags in others.

The Drag on Profitability

The 4% dip in consolidated Adjusted EBITDA can be traced directly to the Specialty Additives and Intermediates divisions. The press release points to the “lingering impact of lower production rates experienced earlier in the fiscal year” and “inflationary cost pressures” as the primary culprits.

This isn't a new issue. A look back at the first half of fiscal 2026 reveals operational headwinds, including startup delays at its Calvert City facility and productivity challenges at its Hopewell plant. While Novo noted that “Plant operations improved during the quarter and profitability increased sequentially,” he also acknowledged, “there is still work to do.” The Specialty Additives segment, despite a 4% sales increase driven by share gains in coatings, saw its Adjusted EBITDA fall from $26 million to $20 million. The higher operating costs stemming from those earlier production inefficiencies ate directly into its margins.

The Intermediates segment tells a similar story. While merchant sales improved on the back of rising demand for NMP in EV battery applications, its Adjusted EBITDA fell from $7 million to $4 million. The company attributed this primarily to lower advanced manufacturing tax credit benefits compared to the prior year, but the segment’s profitability remains a key area of focus.

Ashland’s management is not standing still. The company has been aggressive with pricing actions to offset elevated raw material and freight costs. The success of this strategy is evident in the preserved margins in its stronger segments. The key question moving forward is how quickly these pricing actions and ongoing operational improvements can fully restore profitability in the lagging divisions, especially as the macroeconomic environment remains, in Novo’s words, “uncertain.”

The 'Innovate and Globalize' Growth Engine

Beyond the quarterly operational tug-of-war, Ashland is playing a long game centered on its “globalize and innovate” strategies. Management consistently highlights these initiatives as the primary drivers of future growth, aiming to shift the portfolio toward differentiated, higher-value applications that command stronger margins and deeper customer loyalty. The Q3 results provide tangible evidence that this strategy is gaining traction.

The company’s innovation platforms—spanning from bioresorbable polymers for medical devices to novel cellulosic platforms for consumer goods—are beginning to deliver. In Personal Care, momentum in biofunctional actives and new hair care polymers is a direct result of this R&D focus. In Life Sciences, the push into differentiated injectables and low-nitrite products is helping the company capture share in the resilient and growing pharma market. Earlier in the year, Ashland expressed confidence in achieving $35 million in revenue from these initiatives in fiscal 2026, a target that appears well within reach.

“Our globalize and innovate strategies continued to exceed our targets, driven by strong customer engagement, innovation execution and momentum across our differentiated portfolio,” Novo commented. This strategic pivot is crucial for insulating the company from the cyclicality and commodity pressures that can weigh on its more traditional business lines.

Navigating the Financial Landscape

Despite the profit pressure, Ashland's financial footing appears to be strengthening. The company generated a robust $103 million in Ongoing Free Cash Flow and, critically, reduced its net leverage to 2.4x, returning to its long-term target range. This deleveraging enhances financial flexibility, providing more capacity for strategic investments, innovation, or shareholder returns.

Investors seemingly chose to focus on these positives. The market largely shrugged off the slight EPS miss and the revised full-year adjusted EPS outlook—now projected for low-to-mid-single-digit growth due to a higher tax rate. Instead, the focus was on the strong sales beat and the reaffirmation of full-year sales and Adjusted EBITDA guidance. The positive stock reaction suggests confidence that the operational issues are temporary and that the underlying demand and strategic direction are sound.

As Novo concluded, “We expect continued sequential improvement in the fourth quarter as operational performance steadily improves.” For Ashland, the path forward is clear: maintain the powerful momentum in its core consumer franchises while relentlessly ironing out the production wrinkles that are holding back its full profit potential. Successfully doing so will be the key to carrying its improving earnings momentum into fiscal 2027.